CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Vertex price target raised to $60 from $57 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
Seeking Alpha4d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated ... It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people ...
Reuters1d
Global Market Headlines | Breaking Stock Market News | Reuters
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 20, 2025. REUTERS/Brendan McDermid/File Photo Wall Street's main indexes declined on Friday as ...